LENZ Therapeutics (LENZ) Common Equity (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Common Equity data on file, last reported at $246.5 million in Q1 2026.

• On a quarterly basis, Common Equity rose 28.37% year-over-year to $246.5 million in Q1 2026; TTM through Mar 2026 was $246.5 million, a 28.37% increase from a year earlier, with the FY2025 full-year figure at $284.3 million, up 39.32% from the prior year.
• Common Equity for Q1 2026 stood at $246.5 million, down from $284.3 million in the prior quarter.
• Over the last five years, Common Equity for LENZ reached as high as $361.3 million in Q1 2022 and fell as low as -$92.7 million in Q4 2023.
• Historically, Common Equity has averaged $157.4 million across 5 years, with a median of $198.2 million in 2024.
• Across the five-year window, Common Equity slumped 283.6% in 2023 and jumped 640.29% in 2024, its largest moves.
• Year by year, Common Equity stood at -$24.2 million in 2022, then slumped by 283.6% to -$92.7 million in 2023, then surged by 320.13% to $204.1 million in 2024, then jumped by 39.32% to $284.3 million in 2025, then dropped by 13.31% to $246.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $246.5 million in Q1 2026, $284.3 million in Q4 2025, and $193.9 million in Q3 2025.